Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prognostic Intrathecal Infusion for Chronic Pain
NCT03523000Phase 4Completed
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Oct 2017
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of bupivacaine hydrochloride 0.75% injection, fentanyl in chronic low back pain (CLBP), post-laminectomy syndrome (PLS), Vertebral compression fracture (VCF), sponsored by University Hospitals Cleveland Medical Center. Started Oct 2017; status: completed.
02
Drugs
bupivacaine hydrochloride 0.75% injectionfentanyl
03
Conditions
chronic low back pain (CLBP)post-laminectomy syndrome (PLS)Vertebral compression fracture (VCF)
Beyond the preview
Go deeper on NCT03523000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523000.